PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1498750
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1498750
Single Domain Antibody Platforms Market size was valued at USD 32.30 Million in 2023, expanding at a CAGR of 10.90% from 2024 to 2032.
The technologies and procedures used to produce and employ single domain antibodies (sdAbs), sometimes referred to as nanobodies, are referred to as single domain antibody platforms. These are a particular kind of antibody fragment that is substantially smaller than full-sized antibodies and are composed of a single monomeric variable antibody domain that can selectively bind to a particular antigen.
Single Domain Antibody Platforms Market- Market Dynamics
Growing demand for targeted therapy and the rising prevalence of chronic disorders are expected to propel market demand
The market for single-domain antibody platforms is driven by the growing emphasis on targeted medicines and precision medicine, particularly in oncology. They are perfect for creating tailored treatments because of their strong affinity and specificity. Developments in immunotherapy, especially in the treatment of cancer, have brought attention to the potential of sdAbs in regulating immune responses and specifically targeting tumor cells. These factors are anticipated to accelerate market expansion.
Globally, cancer prevalence is rising, which means there is a big need for novel, efficient treatments like sdAbs. The increasing prevalence of inflammatory disorders like psoriasis, rheumatoid arthritis, and other chronic diseases emphasizes the need for novel treatment approaches. Caplacizumab's regulatory approval for treating thrombotic thrombocytopenic purpura (TTP) is one example of a sdAb-based treatment that validates its clinical potential and spurs additional investment. Many ailments, such as inflammatory, viral, and autoimmune disorders, are being investigated as potential treatments for single-strand antibodies (sdAbs).
Single Domain Antibody Platforms Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.90% over the forecast period (2024-2032)
Based on Platform Type segmentation, the multispecific single domain antibody segment was predicted to show maximum market share in 2023, owing to high demand from diagnostic applications for multi-specific antibodies.
Based on Application segmentation, the diagnostic development segment was the leading Application in 2023, due to the high need for applications in vitro diagnostics.
Based on End User segmentation, the research & development activities segment was the leading End User in 2023, owing to high demand from novel drug development.
On the basis of region, North America was the leading revenue generator in 2023, owing to the presence of advanced healthcare infrastructure.
The Global Single Domain Antibody Platforms Market is segmented on the basis of Platform Type, Application, End User, and Region.
The market is divided into four categories based on Platform Type: multi-specific single-domain antibody, bispecific single-domain antibody, multivalent single-domain antibody, and mono-specific single-domain antibody. The multi-specific single-domain antibody segment dominates the market. Increasing diagnostic development and multiple needs are expected to boost the segment growth.
The market is divided into three categories based on Application: diagnostic development, therapeutic development, and research & development activities. The research & development segment dominates the market. The increasing number of R&D developments by several companies along with government support is spurring the market growth.
The market is divided into five categories based on End Users: diagnostic laboratories, clinical laboratories, academics & research, pharma & biotech companies, and others. The diagnostic laboratories segment dominates the market and is expected to maintain its high dominance during the forecast period. The academic & research segment is anticipated to expand at a significant rate over the forecast period.
Single Domain Antibody Platforms Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominates the global market. The growth is driven by advancements in pharmaceutical therapies and increased R&D investments. The USFDA has positively supported the new drug development and laboratory research activities, which, in turn is booting the regional growth.
The Single Domain Antibody Platforms market is highly competitive in nature with market players facing intense competition. Further, large players in the global market focus on new product development, strategic initiatives like collaboration, and investment to increase their market presence. These strategic initiatives include product innovation, helping the companies to increase their market presence. Key companies in the Single Domain Antibody Platforms Market include GenScript, Creative BioLabs, and Hybrigenics Services, etc.
In the 2023 Antibody Engineering & Therapeutics Conference, held in Sand Diego, OmniAb Inc., presented new scientific data on OmnidAb platform that produces single domain antibodies.
In 2022, GenScript Biotech Corporation completed an agreement with Ligand Pharmaceuticals for OmniAb Platform.